Malignant tumor
Conditions
Interventions
Group A:Paclitaxel-albumin was infused within 30 minutes after the start of the infusion
Sponsors
Ordos Central Hospital, Inner mongolia
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years, pathologically diagnosed malignant tumor to accept Paclitaxel-albumin 260mg/m2 combined with cisplatin 75 mg/m2 or carboplatin AUC >= 5 chemotherapy,and Paclitaxel-albumin was infused in single day; 2.KPS score >=70; 3.Before chemotherapy, liver and kidney function, blood routine, electrocardiogram are normal.Blood tests must meet the requirements of white blood cells > 3.5 * 10^9, neutrophils > 1.5 *10^9, platelets > 85 *10^9, alkaline phosphatase less than 2.5 times of normal value,alanine aminotransferase andaspartate aminotransferase < 2.5 times of normal value, bilirubin 1.5 times of normal value, and creatinine 1.5 times of normal value; 4.No other liver,kidney and blood system diseases. 5.No contraindication of chemotherapy. 6.No intervention (such as surgery) to change body composition before CT and chemotherapy 7.Accept BIA, CT and follow-up. 8.Accept venous blood test after chemotherapy 24 hours. 9.Obtain the patient's informed consent and sign the consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who are allergy in Paclitaxel-albumin or platinum. 2.Patients are bedridden and cannot cooperate with nutritional assessment. 3.Patients with other severe consumptive diseases. 4.Patients who had a long history of hormone use. 5.Patients with HIV, active hepatitis, kidney disease and other diseases that affect drug excretion or drug metabolism 6.Patients who are prophylactic application of long-acting leucovorin before chemotherapy. 7.Patients who terminate anti-tumor treatment voluntarily or fail to perform physical analysis or follow-up of side effects according to the rules. 8.Bilirubin > upper limit of normal value 1.5 times, creatinine > upper limit of normal value 1.5 times. 9.Patients with hepatobiliary pancreatic organ metastasis may affect Paclitaxel-albumin metabolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bioelectrical impedance;muscle area of lumbar vertebra;plasma concentration;Lean body mass;NRS2002 scale;PG-SGA scale; | — |
Countries
China
Contacts
Public ContactLi Quanfu
Ordos Central Hospital, Inner Mongolia Ordos Clinical Medical College, Inner Mongolia Medical University
Outcome results
None listed